A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain

Trial Profile

A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs NKTR 181 (Primary)
  • Indications Musculoskeletal pain; Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMMIT-07
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 20 Mar 2017 According to a Nektar Therapeutics media release, full data from this study will be presented at a medical meeting in the second half of 2017.
    • 20 Mar 2017 Results published in a Nektar Therapeutics Media Release.
    • 20 Mar 2017 Primary endpoint has been met. (Improved chronic back pain relief with NKTR-181 compared to placebo)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top